418 related articles for article (PubMed ID: 16813889)
1. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
[TBL] [Abstract][Full Text] [Related]
2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
3. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
[TBL] [Abstract][Full Text] [Related]
4. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
5. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
[TBL] [Abstract][Full Text] [Related]
8. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
9. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
10. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
11. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
12. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
San Francisco IF; Regan MM; Olumi AF; DeWolf WC
J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
14. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
16. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML
J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993
[TBL] [Abstract][Full Text] [Related]
18. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
Lin DD; Schultz D; Renshaw AA; Rubin MA; Richie JP; D'Amico AV
Urology; 2005 Mar; 65(3):528-32. PubMed ID: 15780370
[TBL] [Abstract][Full Text] [Related]
19. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
20. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
